scholarly journals In vivodetection of lateral-ventral tier nigral degeneration in Parkinson's disease

2017 ◽  
Vol 38 (5) ◽  
pp. 2627-2634 ◽  
Author(s):  
Daniel E. Huddleston ◽  
Jason Langley ◽  
Jan Sedlacik ◽  
Kai Boelmans ◽  
Stewart A. Factor ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nigral Degeneration

scholarly journals Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?

2015 ◽  
Vol 87 (6) ◽  
pp. 633-641 ◽  
Author(s):  
Helen Ling ◽  
Seamus Kearney ◽  
Helen Lai Kuen Yip ◽  
Laura Silveira-Moriyama ◽  
Tamas Revesz ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Nigral Degeneration

scholarly journals The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson’s Disease: A Systematic Literature Review of Pre-Clinical Studies

2021 ◽  
Vol 11 (12) ◽  
pp. 1573
Author(s):  
Samay Prakash ◽  
Wayne G. Carter
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Unmet Need ◽  
Neuroprotective Agents ◽  
Eligibility Criteria ◽  
Neuroprotective Effects ◽  
In Vivo Models ◽  
Anti Inflammatory ◽  
Nigral Degeneration

Currently, there are no pharmacological treatments able to reverse nigral degeneration in Parkinson’s disease (PD), hence the unmet need for the provision of neuroprotective agents. Cannabis-derived phytocannabinoids (CDCs) and resveratrol (RSV) may be useful neuroprotective agents for PD due to their anti-oxidative and anti-inflammatory properties. To evaluate this, we undertook a systematic review of the scientific literature to assess the neuroprotective effects of CDCs and RSV treatments in pre-clinical in vivo animal models of PD. The literature databases MEDLINE, EMBASE, PsychINFO, PubMed, and Web of Science core collection were systematically searched to cover relevant studies. A total of 1034 publications were analyzed, of which 18 met the eligibility criteria for this review. Collectively, the majority of PD rodent studies demonstrated that treatment with CDCs or RSV produced a significant improvement in motor function and mitigated the loss of dopaminergic neurons. Biochemical analysis of rodent brain tissue suggested that neuroprotection was mediated by anti-oxidative, anti-inflammatory, and anti-apoptotic mechanisms. This review highlights the neuroprotective potential of CDCs and RSV for in vivo models of PD and therefore suggests their potential translation to human clinical trials to either ameliorate PD progression and/or be implemented as a prophylactic means to reduce the risk of development of PD.

Nigral degeneration and striatal dopaminergic dysfunction in idiopathic andparkin-linked Parkinson's disease

2005 ◽  
Vol 21 (3) ◽  
pp. 299-305 ◽  
Author(s):  
Michele T.M. Hu ◽  
Christoph Scherfler ◽  
Naheed L. Khan ◽  
Jo V. Hajnal ◽  
Andrew J. Lees ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Dysfunction ◽  
Nigral Degeneration

Dopamine and Migraine: Does Parkinson's Disease Modify Migraine Course?

Cephalalgia ◽  
2000 ◽  
Vol 20 (8) ◽  
pp. 720-723 ◽  
Author(s):  
P Barbanti ◽  
G Fabbrini ◽  
N Vanacore ◽  
A Rum ◽  
GL Lenzi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Positive Family History ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Migraine Prevalence ◽  
History Of ◽  
Nigral Degeneration ◽  
Effect Of Pd ◽  
Positive Effect

As brainstem mechanisms and dopaminergic neurotransmission are involved in migraine pathophysiology, we decided to investigate the course of migraine in Parkinson's disease (PD), the paradigm of brainstem dopaminergic disease. We screened 237 consecutive PD out-patients by direct interview to assess the prevalence of lifetime and current migraine. Moreover, we compared the course of migraine in PD patients with that of otherwise healthy age- (± 3 years) and sex-paired migraine controls in a cross-sectional study. PD patients showed a lifetime migraine prevalence of 27.8% and a current migraine prevalence of 13.1%. A positive family history of migraine was less frequent in PD patients than in controls. The frequency of current migraine was significantly lower in PD patients than in controls (47.0% vs. 68.2%; odds ratio = 0.41, 95% confidence interval = 0.19–0.89). Approximately two-thirds of PD patients reported an improvement in or remission of migraine after PD onset. Effects of menopause on migraine course were similar in patients and controls. These findings suggest that PD might somehow shorten the clinical course of migraine. Possible explanations include a prolonged prophylactic effect by chronic dopaminergic therapy or a positive effect of PD pathophysiology, namely nigral degeneration, on migraine mechanisms.

Sign in / Sign up

Export Citation Format

Share Document